LOGIN  |  REGISTER
Recursion

Xtant Medical Reports Second Quarter 2024 Revenue Growth of 48%

August 08, 2024 | Last Trade: US$0.53 0.0019 -0.35

BELGRADE, MT / ACCESSWIRE / August 8, 2024 / Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the second quarter ended June 30, 2024.

Second Quarter 2024 Financial Highlights

  • Revenue of $29.9 million, up 48%, compared to the prior year quarter

  • Gross margin of 62.1%, up 50 basis points, compared to the prior year quarter

  • Net loss of $3.9 million compared to $2.2 million in the year ago quarter

  • Positive Adjusted EBITDA; Adjusted EBITDA of $0.5 million compared to $0.1 million in the prior year quarter

Recent Business Highlights

  • Recently launched two new amniotic membrane allografts products, SimpliGraft™ and SimpliMax™; while Cortera™ reached record sales and users for the second quarter

  • Signed 15 new distributors in the second quarter

  • Awarded 20 IDN contracts in the second quarter

  • Entered into a $5.0 million private placement on August 7, 2024

Sean Browne, President and CEO of Xtant Medical, stated, "Our second quarter financial results illustrate the positive momentum that is building as we head into the second half of 2024. We delivered strong revenue growth, despite lingering supply chain challenges, which we are addressing through the launch of new, self-produced products. Furthermore, the second quarter marks our fifth consecutive quarter of positive Adjusted EBITDA, and our recent acquisitions are performing at or ahead of our expectations."

Browne continued, "We enter the second half of the year with significant business momentum and, after our recently announced private placement, a stronger balance sheet to support our strategic growth plans. In the second half of 2024, we expect additional new product launches, increased penetration within our distributor network, and an increase in the number of internally produced products, which will coalesce to drive further margin improvement on higher sales and generate positive operating cash flow. We are energized by the prospects for our business and remain committed to our mission of honoring the gift of donation by allowing our patients to live as full and complete a life as possible."

Second Quarter 2024 Financial Results

Total revenue for the three months ended June 30, 2024 was $29.9 million, an increase of 48% compared to $20.2 million in the prior year quarter. The increase is primarily due to the contribution of additional sales resulting from the acquisition of the Surgalign Holdings' hardware and biologics business.

Gross margin for the second quarter of 2024 was 62.1%, compared to 61.6% for the prior year quarter, an increase of 50 basis points. The increase is primarily due to greater scale and improved production efficiency, which was partially offset by increased charges for excess and obsolete inventory and non-absorbed costs and sales mix.

Operating expenses for the second quarter of 2024 totaled $21.5 million, compared to $13.9 million for the second quarter of 2023. The increase was primarily due to additional commission expense resulting from revenue growth, additional compensation expense related to additional headcount and additional stock-based compensation.

Net loss for the second quarter of 2024 was $3.9 million, or $(0.03) per share, compared to a net loss of $2.2 million, or $(0.02) per share in the year ago quarter.

Non-GAAP Adjusted EBITDA for the second quarter of 2024 was $0.5 million, compared to non-GAAP Adjusted EBITDA of $0.1 million for the prior-year period. The Company defines Adjusted EBITDA as net income/loss from operations before depreciation, amortization and interest expense and provision for income taxes, and as further adjusted to add back in or exclude, as applicable, non-cash compensation, acquisition-related expenses, acquisition-related fair value adjustments and foreign currency exchange gains. A calculation and reconciliation of Adjusted EBITDA to net loss can be found in the attached financial tables.

As of June 30, 2024, the Company had $5.4 million of cash and cash equivalents compared to $5.7 million as of December 31, 2023. In a separate release issued today, the Company announced it has entered into a securities purchase agreement with an existing institutional investor to sell $5.0 million shares of its common stock in a private placement at a purchase price of $0.64 per share.

2024 Financial Guidance

Xtant Medical reaffirms its expectation for full year 2024 revenue to $116 million to $120 million, which represents annual revenue growth of approximately 27% to 31% compared to full year 2023 revenue.

Conference Call

Xtant Medical will host a webcast and conference call to discuss second quarter 2024 financial results at 9:00 am ET on Friday, August 9, 2024.

To access the webcast, visit https://www.webcaster4.com/Webcast/Page/3039/50961

To access the conference call, dial 888-999-3182 within the U.S. or 848-280-6330 outside the U.S. Passcode: XTANT Medical Holdings.

A replay of the call will be available on the Investor section of the Company's website at www.xtantmedical.com.

About Xtant Medical Holdings, Inc.

Xtant Medical's mission of honoring the gift of donation so that our patients can live as full and complete a life as possible, is the driving force behind our company. Xtant Medical Holdings, Inc. (www.xtantmedical.com) is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Xtant people are dedicated and talented, operating with the highest integrity to serve our customers.

The symbols ™ and ® denote trademarks and registered trademarks of Xtant Medical Holdings, Inc. or its affiliates, registered as indicated in the United States, and in other countries. All other trademarks and trade names referred to in this release are the property of their respective owners.

Non-GAAP Financial Measures

To supplement the Company's consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles (GAAP), the Company uses certain non-GAAP financial measures in this release, including Adjusted EBITDA. Reconciliations of the non-GAAP financial measures used in this release to the most comparable GAAP measures for the respective periods can be found in tables later in this release. The Company's management believes that the presentation of these measures provides useful information to investors. These measures may assist investors in evaluating the Company's operations, period over period. Management uses the non-GAAP measures in this release internally for evaluation of the performance of the business, including the allocation of resources. Investors should consider non-GAAP financial measures only as a supplement to, not as a substitute for or as superior to, measures of financial performance prepared in accordance with GAAP.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as "intends," ‘‘expects,'' ‘‘anticipates,'' ‘‘plans,'' ‘‘believes,'' ‘‘estimates,'' "continue," "future," ‘‘will,'' "potential," "going forward," "guidance," similar expressions or the negative thereof, and the use of future dates. Forward-looking statements in this release include the Company's financial guidance for 2024 and expectations for additional new product launches, further margin improvement on higher sales and the generation of positive operating cash flow. The Company cautions that its forward-looking statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: the Company's future operating results and financial performance; its ability to increase or maintain revenue; the Company's ability to become operationally self-sustaining and less reliant on third-party manufacturers and suppliers; risks associated with its acquisitions and the integration of those businesses; risk associated with its recently announced private placement; anticipated shortages of stem cells which will adversely affect future revenues; the Company's ability to implement successfully its future growth initiatives and risks associated therewith; possible future impairment charges to long-lived assets and goodwill and write-downs of excess inventory; the ability to remain competitive; the ability to innovate, develop and introduce new products and the success of those products; the ability to engage and retain new and existing independent distributors and agents and qualified personnel and the Company's dependence on key independent agents for a significant portion of its revenue; the effect of labor and hospital staffing shortages on the Company's business, operating results and financial condition, especially when they affect key markets; the effect of inflation, increased interest rates and other recessionary factors and supply chain disruptions; the effect of product sales mix changes on the Company's financial results; government and third-party coverage and reimbursement for Company products; the ability to obtain and maintain regulatory approvals and comply with government regulations; the effect of product liability claims and other litigation to which the Company may be subject; the effect of product recalls and defects; the ability to obtain and protect Company intellectual property and proprietary rights and operate without infringing the rights of others; risks associated with the Company's clinical trials; international risks; the ability to service Company debt, comply with its debt covenants and access additional indebtedness; the ability to obtain additional financing on favorable terms or at all; and other factors. Additional risk factors are contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2023 filed with the Securities and Exchange Commission (SEC) on April 1, 2024 and subsequent SEC filings by the Company, including without limitation its most recent Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2024 anticipated to be filed with the SEC. Investors are encouraged to read the Company's filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by this cautionary statement.

Investor Relations Contact:

Brett Maas
Managing Partner, Hayden IR
This email address is being protected from spambots. You need JavaScript enabled to view it.
(646) 536-7331

XTANT MEDICAL HOLDINGS, INC.
Condensed Consolidated Balance Sheets
(In thousands, except number of shares and par value)

 

 

June 30, 2024

 

 

December 31, 2023

 

 

 

 

 

 

 

 

ASSETS

 

 

 

 

 

 

Current Assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

5,379

 

 

$

5,715

 

Restricted Cash

 

 

99

 

 

 

208

 

Trade accounts receivable, net of allowance for credit losses and doubtful accounts of $1,012 and $920, respectively

 

 

21,187

 

 

 

20,731

 

Inventories

 

 

40,507

 

 

 

36,885

 

Prepaid and other current assets

 

 

1,800

 

 

 

1,330

 

Total current assets

 

 

68,972

 

 

 

64,869

 

 

 

 

 

 

 

 

 

 

Property and equipment, net

 

 

8,837

 

 

 

8,692

 

Right-of -use asset, net

 

 

1,117

 

 

 

1,523

 

Goodwill

 

 

7,302

 

 

 

7,302

 

Intangible assets, net

 

 

9,220

 

 

 

10,085

 

Other assets

 

 

130

 

 

 

141

 

Total Assets

 

$

95,578

 

 

$

92,612

 

 

 

 

 

 

 

 

 

 

LIABILITIES & STOCKHOLDERS' EQUITY

 

 

 

 

 

 

 

 

Current Liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$

6,875

 

 

$

7,054

 

Accrued liabilities

 

 

8,676

 

 

 

10,419

 

Current portion of lease liability

 

 

794

 

 

 

830

 

Current portion of finance lease obligations

 

 

67

 

 

 

65

 

Line of credit

 

 

11,899

 

 

 

4,622

 

Total current liabilities

 

 

28,311

 

 

 

22,990

 

Long-term Liabilities:

 

 

 

 

 

 

 

 

Lease liability, less current portion

 

 

376

 

 

 

759

 

Finance lease obligations, less current portion

 

 

82

 

 

 

116

 

Long-term debt, plus premium and less issuance costs

 

 

21,770

 

 

 

17,167

 

Other liabilities

 

 

34

 

 

 

231

 

Total Liabilities

 

 

50,573

 

 

 

41,263

 

 

 

 

 

 

 

 

 

 

Stockholders' Equity

 

 

 

 

 

 

 

 

Preferred stock, $0.000001 par value; 10,000,000 shares authorized; no shares issued and outstanding

 

 

-

 

 

 

-

 

Common stock, $0.000001 par value; 300,000,000 shares authorized; 130,314,372 shares issued and outstanding as of June 30, 2024 and 130,180,031 shares issued and outstanding as of December 31, 2023

 

 

-

 

 

 

-

 

Additional paid-in capital

 

 

296,451

 

 

 

294,330

 

Accumulated other comprehensive (loss) income

 

 

(175

)

 

 

29

 

Accumulated deficit

 

 

(251,271

)

 

 

(243,010

)

Total Stockholders' Equity

 

 

45,005

 

 

 

51,349

 

 

 

 

 

 

 

 

 

 

Total Liabilities & Stockholders' Equity

 

$

95,578

 

 

$

92,612

 

XTANT MEDICAL HOLDINGS, INC.
Condensed Consolidated Statements of Operations
(Unaudited, in thousands, except number of shares and per share amounts)

 

 

Three Months Ended
June 30,

 

 

Six Months Ended
June 30,

 

 

 

2024

 

 

2023

 

 

2024

 

 

2023

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Revenue

 

$

29,943

 

 

$

20,232

 

 

$

57,816

 

 

$

38,176

 

Cost of sales

 

 

11,361

 

 

 

7,773

 

 

 

21,932

 

 

 

15,180

 

Gross Profit

 

 

18,582

 

 

 

12,459

 

 

 

35,884

 

 

 

22,996

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gross Profit %

 

 

62.1

%

 

 

61.6

%

 

 

62.1

%

 

 

60.2

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating Expenses

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

General and administrative

 

 

7,713

 

 

 

4,954

 

 

 

15,498

 

 

 

9,839

 

Sales and marketing

 

 

13,179

 

 

 

8,716

 

 

 

25,639

 

 

 

15,770

 

Research and development

 

 

636

 

 

 

180

 

 

 

1,163

 

 

 

354

 

Total Operating Expenses

 

 

21,528

 

 

 

13,850

 

 

 

42,300

 

 

 

25,963

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss from Operations

 

 

(2,946

)

 

 

(1,391

)

 

 

(6,416

)

 

 

(2,967

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other Expense

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest expense

 

 

(992

)

 

 

(786

)

 

 

(1,827

)

 

 

(1,360

)

Interest income

 

 

-

 

 

 

-

 

 

 

-

 

 

 

85

 

Unrealized foreign currency translation loss

 

 

118

 

 

 

-

 

 

 

79

 

 

 

-

 

Other income

 

 

(5

)

 

 

-

 

 

 

7

 

 

 

-

 

Total Other Expense

 

 

(879

)

 

 

(786

)

 

 

(1,741

)

 

 

(1,275

)

Net Loss from Operations Before Provision for Income Taxes

 

 

(3,825

)

 

 

(2,177

)

 

 

(8,157

)

 

 

(4,242

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Provision for Income Taxes

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Current and Deferred

 

 

(36

)

 

 

(13

)

 

 

(104

)

 

 

(26

)

Net Loss

 

$

(3,861

)

 

$

(2,190

)

 

$

(8,261

)

 

$

(4,268

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net Loss Per Share:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

$

(0.03

)

 

$

(0.02

)

 

$

(0.06

)

 

$

(0.04

)

Dilutive

 

$

(0.03

)

 

$

(0.02

)

 

$

(0.06

)

 

$

(0.04

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Shares used in the computation:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

 

130,269,710

 

 

 

108,897,048

 

 

 

130,291,796

 

 

 

108,895,327

 

Dilutive

 

 

130,269,710

 

 

 

108,897,048

 

 

 

130,291,796

 

 

 

108,895,327

 

XTANT MEDICAL HOLDINGS, INC.
Condensed Consolidated Statements of Cash Flows
(Unaudited, in thousands)

 

 

Six Months Ended
June 30,

 

 

 

2024

 

 

2023

 

Operating activities:

 

 

 

 

 

 

Net loss

 

$

(8,261

)

 

$

(4,268

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

 

 

Depreciation and amortization

 

 

2,003

 

 

 

1,274

 

Gain on disposal of fixed assets

 

 

(142

)

 

 

(21

)

Non-cash interest

 

 

218

 

 

 

189

 

Stock-based compensation

 

 

2,138

 

 

 

1,056

 

Provision for reserve on accounts receivable

 

 

178

 

 

 

225

 

Provision for excess and obsolete inventory

 

 

388

 

 

 

243

 

Other

 

 

1

 

 

 

3

 

 

 

 

 

 

 

 

 

 

Changes in operating assets and liabilities, net of the effects of the acquisition:

 

 

 

 

 

 

 

 

Accounts receivable

 

 

(688

)

 

 

(3,116

)

Inventories

 

 

(4,130

)

 

 

(1,733

)

Prepaid and other assets

 

 

(469

)

 

 

(330

)

Accounts payable

 

 

(15

)

 

 

954

 

Accrued liabilities

 

 

(2,064

)

 

 

758

 

Net cash used in by operating activities

 

 

(10,843

)

 

 

(4,766

)

Investing activities:

 

 

 

 

 

 

 

 

Purchases of property and equipment

 

 

(1,337

)

 

 

(870

)

Proceeds from sale of fixed assets

 

 

183

 

 

 

55

 

Acquisition of Surgalign SPV, Inc.

 

 

-

 

 

 

(17,000

)

Net cash used in investing activities

 

 

(1,154

)

 

 

(17,815

)

Financing activities:

 

 

 

 

 

 

 

 

Payments on financing leases

 

 

(32

)

 

 

(30

)

Borrowings on line of credit

 

 

59,565

 

 

 

36,256

 

Repayments of line of credit

 

 

(52,288

)

 

 

(34,603

)

Proceeds from issuance of long term debt

 

 

5,000

 

 

 

5,000

 

Debt issuance costs

 

 

(615

)

 

 

(101

)

Payment of taxes from withholding of common stock on vesting of restricted stock units

 

 

(17

)

 

 

-

 

Net cash provided by financing activities

 

 

11,613

 

 

 

6,522

 

 

 

 

 

 

 

 

 

 

Effect of exchange rate changes on cash and cash equivalents and restricted cash

 

 

(61

)

 

 

-

 

 

 

 

 

 

 

 

 

 

Net change in cash and cash equivalents and restricted cash

 

 

(445

)

 

 

(16,059

)

Cash and cash equivalents and restricted cash at beginning of period

 

 

5,923

 

 

 

20,507

 

Cash and cash equivalents and restricted cash at end of period

 

$

5,478

 

 

$

4,448

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Reconciliation of cash and restricted cash reported in the condensed consolidated balance sheets

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

5,379

 

 

$

4,138

 

Restricted cash

 

 

99

 

 

 

310

 

Total cash and restricted cash reported in the condensed consolidated balance sheets

 

$

5,478

 

 

$

4,448

 

XTANT MEDICAL HOLDINGS, INC.
Calculation of Non-GAAP Consolidated EBITDA and Adjusted EBITDA
(Unaudited, in thousands)

 

 

Three Months Ended
June 30,

 

 

Six Months Ended
June 30,

 

 

 

2024

 

 

2023

 

 

2024

 

 

2023

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net Loss

 

$

(3,861

)

 

$

(2,190

)

 

$

(8,261

)

 

$

(4,268

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Depreciation and amortization

 

 

998

 

 

 

803

 

 

 

2,003

 

 

 

1,274

 

Interest expense

 

 

992

 

 

 

786

 

 

 

1,827

 

 

 

1,275

 

Tax expense

 

 

36

 

 

 

13

 

 

 

104

 

 

 

26

 

Non-GAAP EBITDA

 

 

(1,835

)

 

 

(588

)

 

 

(4,327

)

 

 

(1,693

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Non-GAAP EBITDA/Total revenue

 

 

-6.1

%

 

 

-10.7

%

 

 

-7.5

%

 

 

-4.4

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

NON-GAAP ADJUSTED EBITDA CALCULATION

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Non-cash compensation

 

 

1,228

 

 

 

439

 

 

 

2,138

 

 

 

1,056

 

Acquisition-related expenses

 

 

-

 

 

 

254

 

 

 

338

 

 

 

465

 

Acquisition-related fair value adjustments

 

 

1,229

 

 

 

-

 

 

 

2,530

 

 

 

-

 

Foreign currency exchange gain

 

 

(118

)

 

 

-

 

 

 

(79

)

 

 

-

 

Non-GAAP Adjusted EBITDA

 

$

504

 

 

$

105

 

 

$

600

 

 

$

(172

)

Assertio

Stock Quote

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB